0 Reacties
0 aandelen
23 Views
0 voorbeeld
Zoeken
Ontdek nieuwe mensen, nieuwe verbindingen te maken en nieuwe vrienden maken
-
Please log in to like, share and comment!
-
Danaher (DHR) raised its 2026 profit outlook as core sales grew only 3.0%Adjusted earnings per share rose 11.5% in the third quarter while core sales grew 3.0%, and the full-year range moved up by less than the quarter's gain. Cash flow and segment mix tell a narrower story. Danaher Corporation (DHR) reported third-quarter 2026 results on October 21 and raised its full-year adjusted earnings guidance. Adjusted diluted earnings per share reached $2.11, up from $1.89...0 Reacties 0 aandelen 1K Views 0 voorbeeld
-
Natera (NTRA) draws a Buy and a $475 target as Roth/MKM bets on cancer residual disease testsRoth/MKM started coverage of Natera, Inc. (NTRA) at Buy with a $475 target, pointing to wider use of its minimal residual disease blood tests, firmer pricing and a 2027 early detection study readout. Roth/MKM started coverage of Natera, Inc. (NTRA) on Friday, October 23, 2026, with a Buy rating and a $475 price target, Investing.com reported. The firm built its case on the company's cancer...0 Reacties 0 aandelen 1K Views 0 voorbeeld